How often do you monitor urine protein levels for patients with membranous nephropathy for whom you initiate obinutuzumab?

Most studies of obinutuzumab in membranous nephropathy are retrospective, with remission rates of up to 83%. Would monitor UPCR every 1-3 months and check PLA2R every 3 months. Immunological remission (negative PLA2R) precedes clinical remission (one study with 76% at 3 mo and 80% at 6 mo), and clin...

Mother treatment for remembrance GN is very important, and monitoring your protein as well as PLA2R are extremely important as well.

A prompt decrease in PLA2R Ab is expected within a month. Proteinuria usually also falls within a month as well. Afterwards, checking every 2-3 mo should be adequate.